The bacterial immune system we learned to aim

CRISPR lets scientists find one specific sentence in three billion letters of DNA, cut it, and let the cell rewrite it. This page explains how, step by step, and what it is already being used for.

First, what DNA is

Every cell in your body carries a long instruction manual written in a four-letter alphabet: A, T, C and G. The manual is about 3 billion letters long. Stretches of it, called genes, are recipes for proteins, the molecular machines that do almost everything a cell does.

DNA is two strands wound around each other. The strands are not identical; they are complementary. Wherever one strand has an A, the other has a T. Wherever one has a C, the other has a G. That pairing rule is the whole reason CRISPR works: if you know one strand, you know the other, and you can build a short molecule that will stick to exactly one place.

A single wrong letter can matter. Sickle cell disease, for example, comes from one changed letter in the recipe for haemoglobin, the protein that carries oxygen in red blood cells.

Two strands, always paired: A with T, C with G. One gene might be a few thousand of these letters long.
one strand
its complementary partner

Where CRISPR comes from

CRISPR was not invented. It was found. Bacteria are attacked by viruses, and over billions of years they evolved an immune system that remembers past infections.1 The awkward name, Clustered Regularly Interspaced Short Palindromic Repeats, just describes what that memory looks like in the bacterium's DNA: a row of stored snippets of viral DNA, separated by repeated spacer sequences.

The system works in three moves.

1. A virus attacks viral DNA bacterium 2. It keeps a snippet new memory the CRISPR array: repeats, with snippets between 3. Next time, it cuts the snippet guides a cutting protein straight to the virus
A bacterium files away a piece of each virus it survives. If that virus returns, a protein carrying the matching snippet finds the viral DNA and cuts it.

The leap that won the 2020 Nobel Prize in Chemistry was realising that move three could be pointed at anything. Emmanuelle Charpentier, studying the bacterium Streptococcus pyogenes, discovered a previously unknown RNA molecule (tracrRNA) that is part of this defence. In 2011 she began working with Jennifer Doudna; together they rebuilt the system in a test tube, simplified it, and showed it could be reprogrammed to cut any DNA at a chosen site.1 The Nobel committee called it "genetic scissors".

The two parts

The most common version of the tool, CRISPR-Cas9, has only two components.2

The scissors: Cas9

Cas9 is a protein. Think of it as a machine with two jobs: read DNA, and cut it. On its own it is aimless. It cannot choose where to cut.

The address: the guide RNA

The guide RNA is a short molecule, about 100 letters long, that snaps into Cas9. Twenty of those letters are the address. Because of the pairing rule from the previous section, a 20-letter address written in RNA will stick to exactly one 20-letter stretch of DNA that complements it. Change the 20 letters and you change where Cas9 cuts. That is the entire programming step.

One more rule matters. Cas9 will only bind and cut if the target is sitting right next to a short signature in the DNA called a PAM. For the Cas9 most labs use, that signature is any letter followed by two Gs, written NGG.3 Without a PAM, even a perfect 20-letter match is ignored.4 The PAM is also how the system avoids cutting the bacterium's own stored memories: the snippets in the CRISPR array have no PAM beside them.

Cas9 protein GACUUACGAUCA… scaffold: holds on to Cas9 address: 20 letters, chosen by you How it finds the spot 1. look for a PAM (NGG) 2. unzip the DNA beside it 3. test the 20 letters 4. all match? cut both strands any mismatch? let go, keep looking

How the cut happens

Step through it below. The DNA is shortened so it fits on screen: a real address is 20 letters, this one is 12. Everything else follows the real mechanism, including the decoy stop, the unzipping, and where the cut lands.

Cas9 + guide RNA
  • 1 Load
  • 2 Scan
  • 3 Decoy
  • 4 Match
  • 5 Cut
  • 6 Repair
top strand (has the PAM)
bottom strand (guide pairs here)
guide RNA address
Cas9
repair template

Why the decoy matters

NGG shows up every few dozen letters across the genome, so Cas9 stops at a PAM constantly. At each stop it bends and partially unwinds the DNA, pulling a few letters out so the guide can test them.5 Matching starts at the PAM end and works outward; if the first letters fail, Cas9 lets go within a fraction of a second and moves on.4 Only a site where all the letters pair up triggers the cutting machinery. Most of Cas9's life is spent rejecting near-misses.

Where the cut lands

When the match is complete, Cas9 cuts both strands at the same place, three letters away from the PAM.6 That produces a clean break straight through the double helix. Cas9 itself has now done its whole job. What happens next is up to the cell.

How the cell repairs it

This is the part most explanations skip, and it is where the actual editing happens. Cas9 does not edit anything; it only breaks. Cells treat a double-strand break as an emergency and repair it within hours, using one of two systems.67

Patch it fast (non-homologous end joining)

The default. Repair proteins grab the two loose ends and glue them back together. It is quick and sloppy: a few letters are often lost or added at the seam. Inside a gene, that usually shifts the reading frame, the way deleting one letter from "the cat ate the rat" gives "hec ata tet her at". The recipe becomes gibberish and the gene stops working. If your goal is to switch a gene off, this sloppiness is exactly what you want.

Copy from a template (homology-directed repair)

If a matching piece of DNA is nearby, the cell can use it as a reference and copy from it while repairing. Scientists exploit this by supplying a template that matches the surroundings of the cut but carries the change they want: a corrected letter, or a new segment. The cell copies the change in. This is precise, but it works less often than patching, and mostly in cells that are actively dividing.7

Patch it fast two ends, glued back; a letter is lost reading frame shifts, gene disabled useful when the goal is "turn this gene off" Copy from a template a supplied strand is used as the reference one letter corrected, gene intact precise, but succeeds less often

Newer editors that don't break the DNA

Cutting both strands is powerful but blunt. Since 2016, researchers have built variants of Cas9 that keep the address-finding ability but swap the scissors for something gentler.89

Standard Cas9

Finds the address, cuts both strands, hands the problem to the cell's repair crew. Best for disabling a gene.

Base editor

A disabled Cas9 carrying a chemical that rewrites one letter in place (C to T, or A to G) without breaking the strands. No cut, so no sloppy repair. Limited to those swaps.8

Prime editor

A Cas9 that nicks one strand and carries its own writing template. It can make any single-letter change plus small insertions and deletions.9

What it is being used for

Everything below is dated and sourced, because this field moves fast. As of September 2026:

  1. Charpentier reports tracrRNA; with Doudna she rebuilds and reprograms the cutting system in a test tube.1 Labs worldwide adopt it within months.

  2. The Royal Swedish Academy of Sciences awards the two of them the Nobel Prize in Chemistry "for the development of a method for genome editing".1

  3. The UK's medicines regulator approves Casgevy, the first CRISPR-based medicine, for sickle cell disease and transfusion-dependent beta thalassaemia.10

  4. The US FDA approves Casgevy for sickle cell disease in patients 12 and older with recurrent pain crises.1011 How it works: a patient's blood stem cells are removed, Cas9 is used to disable a switch that normally turns off fetal haemoglobin after birth, and the edited cells are returned after high-intensity chemotherapy clears space for them. Fetal haemoglobin doesn't sickle, so the crises stop.12

  5. FDA approval extended to transfusion-dependent beta thalassaemia.11

  6. KJ Muldoon, an infant with an ultra-rare liver enzyme deficiency, receives the first CRISPR therapy designed for a single patient, built by Children's Hospital of Philadelphia and Penn Medicine using base editing. The case was announced in May 2025; as of early 2026 he was walking with mild symptoms of a previously fatal condition.1314

  7. The FDA announces a regulatory pathway aimed at individualised gene-editing therapies, and teams at the Innovative Genomics Institute prepare a second bespoke case.1516

  8. FDA extends Casgevy to patients as young as 2.12

  9. Crops: base editing has been used for herbicide-tolerant rice, improved rice grain quality, and nutritional changes in tomato, maize and wheat.8 Research: CRISPR is now a routine tool for switching genes off in cell lines and animals to learn what they do, and a "dead" Cas9 that binds without cutting is used to turn genes up or down and even to light up specific DNA regions under a microscope.9

What it can't do yet

Delivery. Cas9 and its guide are large molecules, and getting them into the right cells inside a living person is the hardest unsolved problem. Casgevy sidesteps it by editing cells outside the body. Editing the liver works because the liver naturally collects the lipid particles used to carry the editor. Most other tissues are still out of reach.9

Off-target cuts. A near-match with one or two wrong letters can occasionally still be cut. Guides are now designed by software to avoid this, and higher-fidelity Cas9 variants exist, but it has to be checked for every new therapy.8

Repair is not fully controllable. Template-based repair is inefficient, and end joining is random by nature. Base and prime editors exist largely to route around this.

Cost and access. Casgevy is a one-time treatment, but it requires a stem-cell transplant procedure and specialist centres.11

Sources

Every factual claim above traces to one of these. Where the text summarises a paper, follow the link for the original wording.

  1. The Royal Swedish Academy of Sciences, press release for the Nobel Prize in Chemistry 2020 (7 Oct 2020), nobelprize.org; reported by the American Society of Gene & Cell Therapy, asgct.org, and The ASCO Post, ascopost.com.
  2. Zhang lab summary of the two-component system and repair outcomes, Fig. 2, BioMed Research International 2018, PMC6167567.
  3. Anders C. et al., "Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease", Nature 2014, PubMed 25079318.
  4. Sternberg S.H. et al., "DNA interrogation by the CRISPR RNA-guided endonuclease Cas9", Nature 2014, PubMed 24476820.
  5. Cofsky J.C. et al., "CRISPR-Cas9 bends and twists DNA to read its sequence", Nature Structural & Molecular Biology 2022, PMC9189902.
  6. Cut position three base pairs from the PAM and the NHEJ/HDR outcomes: PMC6167567, Fig. 2.
  7. Journal of Clinical Investigation 2022, Fig. 1, "CRISPR/Cas9 nuclease editing", PMC8718140.
  8. Aliciaslan et al., "Advances in CRISPR Base Editing", Journal of Cellular and Molecular Medicine, April 2026, PMC13109818.
  9. "Engineering delivery platforms for CRISPR-Cas and their applications in healthcare, agriculture and beyond", PMC12865601; and "Emerging trends in prime editing", Experimental & Molecular Medicine 2025, nature.com.
  10. "CRISPR Therapy of Sickle Cell Disease: The Dawning of the Gene Editing Era", The American Journal of Medicine, Jan 2024, amjmed.com; FDA press release, 8 Dec 2023, fda.gov.
  11. Vertex / CRISPR Therapeutics approval announcement, 8 Dec 2023, crisprtx.com; approval history, drugs.com.
  12. FDA press release, "FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease", 1 July 2026, fda.gov.
  13. Scientific American, "In World First, Baby Receives Personalized CRISPR Gene-Editing Treatment", May 2025, scientificamerican.com.
  14. Life Science Daily, "CRISPR Gene Editing in 2026", June 2026, lifesciencedaily.news.
  15. BioSpace, "Gene therapy leaders aim to help more Baby KJs with novel regulatory models", April 2026, biospace.com.
  16. "Building CRISPR-Based Gene-Editing Platforms for Personalized Medicine", Genes 17(6):631, May 2026, doi.org; Innovative Genomics Institute clinical-trials tracker, innovativegenomics.org.